Key Metrics 
Check Before You Invest 
DeciZen 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Aarti Pharmalabs Ltd (AARTIPHARM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543748 NSE: AARTIPHARM Pharmaceuticals & Drugs | Small Cap | Aarti Pharmalabs Share Price
₹867.75 2.30 (0.27%)
As on 02-Sep'26 16:59
Aarti Pharmalabs Ltd (AARTIPHARM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543748 NSE: AARTIPHARM Pharmaceuticals & Drugs | Small Cap | Aarti Pharmalabs Share Price
₹867.75 2.30 (0.27%)
As on 02-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹7,869 Cr.
Current Price
₹867.8
52-Week Low / High
₹584 / 946
TTM EPS
₹23
TTM Sales
₹1,957 Cr.
Book Value per Share
₹226.1
P/E Ratio
37.81
Higher than its 5-year historical median
Industry PE
54.5
Price to Book (P/B)
3.84
Higher than its 5-year historical median
Price to Sales (P/S)
4.02
Higher than its 5-year historical median
EV/EBITDA
19.15
Higher than its 5-year historical median
Dividend Yield
0.4%
Profitability Efficiency
Return on Equity (ROE)
9.22%
In line with industry median
Return on Capital Employed (ROCE)
11.46%
In line with industry median
Return on Assets (ROA)
5.83%
Operating Profit Margin
22.6%
Net Profit Margin
9.8%
Gross Profit Margin
19%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
1.48%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-12.57%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-31.53%
Asset Quality
Promoter Holding
42.86%
Pledged shares (%) of Promoter's holding (%)
11.08%
Reserves
₹2,005 Cr.
Equity
₹45.3 Cr.
Face Value
₹5
All Time Low / High
₹269.00 / 971.50
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Aarti Pharmalabs Ltd a good quality company?
Aarti Pharmalabs Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Aarti Pharmalabs Ltd performance compare with that of its Peers?
Revenue growth of Aarti Pharmalabs Ltd vs industry peers?
Aarti Pharmalabs Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 5.82%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Aarti Pharmalabs Ltd?
Promoters hold 42.86% of the Aarti Pharmalabs Ltd, with 11.08% of their stake pledged, indicating high pledge risk.
Stock return of Aarti Pharmalabs Ltd over the last decade?
Over the last 3 year(s), the stock has delivered a CAGR of 30.86% based on the current price.
DeciZen - make an informed investing decision on Aarti Pharmalabs
Decision Maker
Standalone basis
1. Right Stock
10 Year X-ray Pro
Long Term Prospect
2. Right Price
3. Right Time ⓘ
#Likely Future 5 Year CAGR.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Aarti Pharmalabs Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | -8.1% | -1.9% | 18% | 15.6% | 16.6% | 17.6% | 11.5% | - |
| Value Creation Index ⓘ | NA | NA | NA | -1.6 | -1.1 | 0.3 | 0.1 | 0.2 | 0.3 | -0.2 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 0 | 941 | 1,511 | 1,502 | 1,771 | 1,798 | 1,957 |
| Sales YoY Gr. | - | NA | NA | NA | NA | NA | 60.6% | -0.6% | 17.9% | 1.5% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | -0.8 | -0.2 | 4,268.2 | 19 | 22.1 | 28.3 | 22.2 | 23 |
| YoY Gr. | - | NA | NA | NA | NA | NA | -99.6% | 16.6% | 27.9% | -21.4% | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 9.3 | 9.1 | 49,558.5 | 158.7 | 178.9 | 203.3 | 218.3 | 226.1 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | -0 | -0 | 107 | 172 | 200 | 256 | 201 | 208 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | -0 | 0 | -64.8 | 216 | 184 | 339 | 257 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | -5 | 1 | 1.4 | 1.2 | 2.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 6% | 1.5% | ||||
| Adj EPS ⓘ | NA | NA | 5.5% | -21.4% | ||||
| BVPSⓘ | NA | 88.7% | 11.2% | 7.4% | ||||
| Share Price | - | - | 30.7% | -1.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 0 | -8.1 | -2 | 16.6 | 12.6 | 13.1 | 14.8 | 10.5 | 10.3 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | 19.1 | 20.4 | 23 | 24.1 | 22.6 | 22.7 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | 11.3 | 11.4 | 13.3 | 14.5 | 11.2 | 10.6 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0.1 | 0.3 | 0.1 | 0.2 | 0.2 | 0.4 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 0 | 163 | 219 | 256 | 244 | 272 | 124 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 0 | 116 | 150 | 166 | 150 | 164 | 46 |
Valuation of Aarti Pharmalabs - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 11.03 | 11.08 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 941 | 1,511 | 1,502 | 1,771 | 1,798 |
| Operating Expenses ⓘ + | 0 | 0 | 761 | 1,203 | 1,156 | 1,345 | 1,425 |
| Operating Profit ⓘ | -0 | -0 | 180 | 308 | 346 | 427 | 373 |
| Operating Profit Margin (%) | - | - | 19.1% | 20.4% | 23.0% | 24.1% | 20.7% |
| Other Income ⓘ + | 0 | 0 | 3 | 1 | 11 | 14 | 15 |
| Interest ⓘ | 0 | 0 | 11 | 20 | 17 | 26 | 47 |
| Depreciation ⓘ | 0 | 0 | 37 | 56 | 66 | 79 | 104 |
| Profit Before Tax ⓘ | -0 | -0 | 134 | 233 | 275 | 336 | 234 |
| Tax ⓘ | 0 | 0 | 27 | 62 | 74 | 79 | 58 |
| Profit After Tax | -0 | -0 | 107 | 172 | 201 | 257 | 176 |
| PAT Margin (%) | - | - | 11.3% | 11.4% | 13.4% | 14.5% | 9.8% |
| Adjusted EPS (₹) | -0.8 | -0.2 | 4,269.1 | 19.0 | 22.1 | 28.4 | 19.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 10.60% | 13.60% | 17.60% | 18% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 0 | 0 | 1,239 | 1,439 | 1,621 | 1,842 | 1,979 | ||||
| Debt + | 0 | 0 | 325 | 207 | 251 | 395 | 643 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Trade Payables | 0 | 0 | 132 | 212 | 255 | 249 | 324 | ||||
| Others Liabilities ⓘ | 0 | 0 | 132 | 119 | 170 | 234 | 381 | ||||
| Total Liabilities ⓘ | 0 | 0 | 1,827 | 1,976 | 2,297 | 2,720 | 3,328 | ||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 0 | 0 | 701 | 848 | 953 | 1,059 | 1,437 | ||||
| CWIP ⓘ | 0 | 0 | 187 | 102 | 137 | 369 | 393 | ||||
| Investments ⓘ | 0 | 0 | 40 | 55 | 62 | 57 | 44 | ||||
| Inventories | 0 | 0 | 444 | 538 | 582 | 544 | 636 | ||||
| Trade Receivables | 0 | 0 | 304 | 372 | 449 | 553 | 587 | ||||
| Cash Equivalents | 0 | 0 | 56 | 0 | 4 | 4 | 7 | ||||
| Others Assets ⓘ | 0 | 0 | 93 | 61 | 110 | 134 | 224 | ||||
| Total Assets ⓘ | 0 | 0 | 1,827 | 1,976 | 2,297 | 2,720 | 3,328 | ||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -0 | 0 | -65 | 216 | 184 | 339 | 257 |
| Cash Flow From Investing Activity ⓘ + | 0 | 0 | -134 | -116 | -184 | -418 | -425 |
| Cash Flow From Financing Activity ⓘ + | 0 | 0 | 255 | -157 | 4 | 79 | 171 |
| Net Cash Flow ⓘ | 0 | 0 | 56 | -56 | 4 | -1 | 3 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | N/A | 17.23 | 12.83 | 13.11 | 14.86 | 9.22 | |||
| ROCE (%) | N/A | N/A | 18.03 | 15.6 | 16.55 | 17.61 | 11.46 | |||
| Asset Turnover Ratio | 0 | 0 | 1.03 | 0.79 | 0.7 | 0.71 | 0.59 | |||
| PAT to CFO Conversion(x) | N/A | N/A | -0.61 | 1.26 | 0.92 | 1.32 | 1.46 | |||
| Working Capital Days | ||||||||||
| Receivable Days | 0 | 0 | 118 | 81.60 | 99.70 | 103.20 | 115.70 | |||
| Inventory Days | 0 | 0 | 172.40 | 118.60 | 136.10 | 116.10 | 119.90 | |||
| Payable Days | 0 | 0 | 53.20 | 76.80 | 113.40 | 110.50 | 127.40 | |||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Aarti Pharmalabs Ltd FAQs
The current trading price of Aarti Pharmalabs on 02-Sep-2026 16:59 is ₹867.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Sep-2026 the market cap of Aarti Pharmalabs stood at ₹7,868.7 Cr
The latest P/E ratio of Aarti Pharmalabs as of 01-Sep-2026 is 37.81.
The latest P/B ratio of Aarti Pharmalabs as of 01-Sep-2026 is 3.84.
The 52-week high of Aarti Pharmalabs is ₹946.5 and the 52-week low is ₹583.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aarti Pharmalabs is ₹1,957 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Aarti Pharmalabs Ltd is a average quality company.
The key valuation ratios of Aarti Pharmalabs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Aarti Pharmalabs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Aarti Pharmalabs Ltd
Aarti Pharmalabs Limited (APL) (Formerly known as Aarti Organics Limited) is a leading Indian manufacturer of Pharmaceuticals and Nutraceuticals with a global footprint.
Over the past two decades, enabled by cutting-edge R&D and manufacturing capabilities APL has evolved as a reliable partner of choice for generic players and innovators across the globe. The company specialises in generic APIs, generic intermediates, and xanthine derivatives. It delivers CDMO services for drug substance/NCE development and manufacturing for innovative pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products.
With the biggest manufacturing capacity in India for its flagship product ‘Caffeine’ APL has emerged as a preferred partner for the Beverages, Nutraceuticals manufacturing companies, and Pharmaceuticals Industries across the world.
Business area of the company
The company is an, internationally recognised manufacturer of Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, New Chemical Entities (NCE), and xanthine derivatives situated in India. In order to build a sustainable future, it integrates process chemistry proficiency (recipe focus) with scale-up engineering proficiency (asset utilisation).
Products and services
- API
- Intermediates
- CDMO Services
- Caffeine
- Xanthine Derivatives
- Acid & Allied
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
